{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:44:30Z","timestamp":1788349470452,"version":"build-2803163510"},"reference-count":104,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:00:00Z","timestamp":1757203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The current classification of Hodgkin lymphoma (HL) is the result of an integrated approach that combines the evaluation of morphological patterns, immunophenotypic characteristics, molecular features, and clinical presentation. Evolving from its origins based solely on histological observation to the latest updates in the WHO 5th Edition, this system has become an essential tool for accurate diagnosis and personalized therapeutic strategies. Each subtype of classic HL (cHL)\u2014nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted\u2014exhibits distinctive pathological and clinical features, now better understood through multidisciplinary studies and international collaborations. HL also includes nodular lymphocyte-predominant HL (NLPHL), a distinct entity with unique morphologic, immunophenotypic, and clinical features. A hallmark morphological feature of cHL is the presence of Hodgkin and Reed-Sternberg (HRS) cells, large and often multinucleated cells derived from B lymphocytes that have lost their typical B-cell phenotype. Identifying these cells is critical for diagnosis and for differentiating HL from other hematologic malignancies. HL is characterized by the rarity of malignant cells, a high curability rate, and a rich immune cell microenvironment that is both shaped and exploited by the tumor. Understanding these core aspects paves the way for exploring the role of immunologic and genetic biomarkers in refining classification, enhancing diagnosis, improving prognostic assessment, and guiding therapy for patients with cHL.<\/jats:p>","DOI":"10.3390\/cancers17172929","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T10:29:07Z","timestamp":1757327347000},"page":"2929","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hodgkin Lymphoma Classification\u2014From Historical Concepts to Current Refinements"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2211-639X","authenticated-orcid":false,"given":"Antonino","family":"Carbone","sequence":"first","affiliation":[{"name":"Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, National Cancer Institute, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9390-5645","authenticated-orcid":false,"given":"Mohamed N.","family":"Alibrahim","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood.V95.4.1443.004k55_1443_1450","article-title":"Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription","volume":"95","author":"Marafioti","year":"2000","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.184.4.1495","article-title":"Hodgkin and Reed-Sternberg cells in Hodgkin\u2019s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells","volume":"184","author":"Kanzler","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0950-3536(96)80018-7","article-title":"The epidemiology of Hodgkin\u2019s disease","volume":"9","author":"Glaser","year":"1996","journal-title":"Bailli\u00e8re\u2019s Clin. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.33948","article-title":"Global patterns of Hodgkin lymphoma incidence and mortality in 2020 and a prediction of the future burden in 2040","volume":"150","author":"Singh","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_7","unstructured":"Kaseb, H., and Babiker, H.M. (2023). Hodgkin Lymphoma. StatPearls [Internet], StatPearls."},{"key":"ref_8","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2012). A Review of Human Carcinogens: Part B: Biological Agents, World Health Organisation."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Carbone, A., and Gloghini, A. (2018). Epstein Barr Virus-Associated Hodgkin Lymphoma. Cancers, 10.","DOI":"10.3390\/cancers10060163"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Shannon-Lowe, C., Rickinson, A.B., and Bell, A.I. (2017). Epstein\u2013Barr virus-associated lymphomas. Philos. Trans. R. Soc. B Biol. Sci., 372.","DOI":"10.1098\/rstb.2016.0271"},{"key":"ref_11","first-page":"31","article-title":"HIV\/AIDS Associated Lymphoma: Review","volume":"12","author":"Berhan","year":"2022","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/ijc.30473","article-title":"The impact of EBV and HIV infection on the microenvironmental niche underlying H odgkin lymphoma pathogenesis","volume":"140","author":"Carbone","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.molmed.2024.10.004","article-title":"Advances in Hodgkin lymphoma research","volume":"31","author":"Kuppers","year":"2025","journal-title":"Trends Mol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Aoki, T., Wierzbicki, K., Sun, S., Steidl, C., and Giulino-Roth, L. (2025). Tumor-microenvironment and molecular biology of classic Hodgkin lymphoma in children, adolescents, and young adults. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1515250"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-24-0942","article-title":"Multiplexed Spatial Profiling of Hodgkin Reed-Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma","volume":"30","author":"Pourmaleki","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"ref_17","unstructured":"International Agency for Research on Cancer (2023). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC. [5th ed.]."},{"key":"ref_18","unstructured":"Arber, D.A. (2025). The International Consensus Classification of Myeloid and Lymphoid Neoplasms, Wolters Kluwer."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM194401062300101","article-title":"Hodgkin\u2019s disease: General considerations","volume":"230","author":"Jackson","year":"1944","journal-title":"N. Engl. J. Med."},{"key":"ref_20","unstructured":"Rappaport, H. (1966). Tumors of the Hematopoietic System, Armed Forces Institute of Pathology."},{"key":"ref_21","first-page":"1311","article-title":"Report of the nomenclature committee","volume":"26","author":"Lukes","year":"1966","journal-title":"Cancer Res."},{"key":"ref_22","first-page":"1063","article-title":"The pathology and nomenclature of Hodgkin\u2019s disease","volume":"26","author":"Lukes","year":"1966","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"ref_24","unstructured":"International Agency for Research on Cancer (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC."},{"key":"ref_25","unstructured":"International Agency for Research on Cancer (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC. [Revised 4th ed.]."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1182\/blood-2023-182919","article-title":"EBV Prevalence and Overall Survival in the Multi ethnic Study of Hodgkin Lymphoma (MESH)","volume":"142","author":"Lam","year":"2023","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1182\/blood-2023-178257","article-title":"Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults","volume":"142","author":"Rossi","year":"2023","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Fend, F., and Quintanilla-Martinez, L. (2018). Hodgkin lymphoma. Hematopathology, Elsevier. [3rd ed.].","DOI":"10.1016\/B978-0-323-47913-4.00011-2"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Navarro, J.T., Molto, J., Tapia, G., and Ribera, J.M. (2021). Hodgkin Lymphoma in People Living with HIV. Cancers, 13.","DOI":"10.20944\/preprints202108.0420.v1"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/modpathol.2009.54","article-title":"Lymphocyte-rich classical Hodgkin\u2019s lymphoma: Distinctive tumor and microenvironment markers","volume":"22","author":"Salcedo","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/10428190902930488","article-title":"Lymphocyte depleted Hodgkin lymphoma: An evaluation with immunophenotyping and genetic analysis","volume":"50","author":"Slack","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00428-008-0683-9","article-title":"Lymphocyte-depleted classic Hodgkin lymphoma-a neglected entity?","volume":"453","author":"Benharroch","year":"2008","journal-title":"Virchows Arch."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cyto.b.22045","article-title":"A comparison and review of the flow cytometric findings in classic Hodgkin lymphoma, nodular lymphocyte predominant Hodgkin lymphoma, T cell\/histiocyte rich large B cell lymphoma, and primary mediastinal large B cell lymphoma","volume":"102","author":"Martig","year":"2022","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_35","first-page":"3476","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma: Advances in disease biology, risk stratification, and treatment","volume":"109","author":"Salvaris","year":"2024","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/asheducation-2017.1.324","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma: A unique disease deserving unique management","volume":"2017","author":"Eichenauer","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12308-011-0104-x","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells","volume":"4","author":"Seliem","year":"2011","journal-title":"J. Hematop."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14218\/JCTP.2024.00015","article-title":"Histopathologic Features and Differential Diagnosis in Challenging Cases of Nodular Lymphocyte Predominant B-cell Lymphoma\/Nodular Lymphocyte Predominant Hodgkin Lymphoma","volume":"4","author":"Ding","year":"2024","journal-title":"J. Clin. Transl. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e70080","DOI":"10.1002\/hon.70080","article-title":"Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Update on Biology and Treatment","volume":"43","author":"Borchmann","year":"2025","journal-title":"Hematol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation","volume":"27","author":"Fan","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hartmann, S., Eray, M., Doring, C., Lehtinen, T., Brunnberg, U., Kujala, P., Vornanen, M., and Hansmann, M.L. (2014). Diffuse large B cell lymphoma derived from nodular lymphocyte predominant Hodgkin lymphoma presents with variable histopathology. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-332"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.15614","article-title":"Diagnosis of Hodgkin lymphoma in the modern era","volume":"184","author":"Wang","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1002\/cncr.30824","article-title":"Hodgkin lymphoma classification: Are we at a crossroads?","volume":"123","author":"Carbone","year":"2017","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2003-02-0626","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell\/histiocyte-rich B-cell lymphoma: Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell\/histiocyte-rich B-cell lymphoma","volume":"102","author":"Torlakovic","year":"2003","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood.2020005546","article-title":"Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58","volume":"136","author":"Veldman","year":"2020","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1053\/j.seminhematol.2024.05.001","article-title":"The biology of classical Hodgkin lymphoma","volume":"64","author":"Kosydar","year":"2024","journal-title":"Semin. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.659","article-title":"The Reed-Sternberg cell in classical Hodgkin\u2019s disease","volume":"19","author":"Chan","year":"2001","journal-title":"Hematol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"101271","DOI":"10.1016\/j.blre.2025.101271","article-title":"Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies","volume":"71","author":"Alibrahim","year":"2025","journal-title":"Blood Rev."},{"key":"ref_50","unstructured":"International Agency for Research on Cancer (2001). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC. [3rd ed.]."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3816\/CLM.2009.n.042","article-title":"Hodgkin lymphoma: An update on its biology with new insights into classification","volume":"9","author":"Mani","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/2278-0513.113630","article-title":"Update on Hodgkin\u2032 s lymphoma","volume":"2","author":"Sabharwal","year":"2013","journal-title":"Clin. Cancer Investig. J."},{"key":"ref_53","first-page":"1889","article-title":"European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: Histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes","volume":"96","author":"Anagnostopoulos","year":"2000","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1200\/JCO.2005.17.970","article-title":"Lymphocyte-rich classical Hodgkin\u2019s lymphoma: Clinical presentation and treatment outcome in 100 patients treated within German Hodgkin\u2019s Study Group trials","volume":"23","author":"Haverkamp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_55","first-page":"20","article-title":"What Is Still Unclear or Unresolved in Classic Hodgkin Lymphoma Pathobiology","volume":"6","author":"Carbone","year":"2025","journal-title":"Diagn. Treat."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PAP.0000000000000119","article-title":"Primary Mediastinal Classical Hodgkin Lymphoma","volume":"23","author":"Moran","year":"2016","journal-title":"Adv. Anat. Pathol."},{"key":"ref_57","unstructured":"Thida, A.M., and Tun, A.M. (2025). Lymphocyte Depleted Hodgkin Lymphoma. StatPearls, StatPearls Publishing."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood.2019004044","article-title":"How I treat nodular lymphocyte-predominant Hodgkin lymphoma","volume":"136","author":"Eichenauer","year":"2020","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Alibrahim, M.N., Gloghini, A., and Carbone, A. (2025). Immune Deficiency\/Dysregulation-Associated EBV-Positive Classic Hodgkin Lymphoma. Cancers, 17.","DOI":"10.3390\/cancers17091433"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1309\/YCH8DWUFFQBKGPVB","article-title":"The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma","volume":"120","author":"Browne","year":"2003","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/1521-4141(200002)30:2<458::AID-IMMU458>3.0.CO;2-5","article-title":"The BOB. 1\/OBF. 1 co-activator is essential for octamer-dependent transcription in B cells","volume":"30","author":"Laumen","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Dumitru, A.V., Tapoi, D.A., Halcu, G., Munteanu, O., Dumitrascu, D.I., Ceausu, M.C., and Gheorghisan-Galateanu, A.A. (2023). The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment. Cells, 12.","DOI":"10.3390\/cells12131783"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"100949","DOI":"10.1016\/j.blre.2022.100949","article-title":"A review of pathobiology and therapies for classic Hodgkin lymphoma","volume":"55","author":"Khan","year":"2022","journal-title":"Blood Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/PAS.0000000000000242","article-title":"A single slide multiplex assay for the evaluation of classical Hodgkin lymphoma","volume":"38","author":"Lazare","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.anndiagpath.2019.02.001","article-title":"American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma","volume":"39","author":"Dogan","year":"2019","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/bloodadvances.2017009472","article-title":"Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL","volume":"1","author":"Pilichowska","year":"2017","journal-title":"Blood Adv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3324\/haematol.2011.043026","article-title":"Mediastinal gray zone lymphoma","volume":"96","author":"Fend","year":"2011","journal-title":"Haematologica"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41379-021-00983-8","article-title":"Clonality assessment and detection of clonal diversity in classic Hodgkin lymphoma by next-generation sequencing of immunoglobulin gene rearrangements","volume":"35","author":"Rijntjes","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00277-025-06328-8","article-title":"Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics","volume":"104","author":"Veltmaat","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e433502","DOI":"10.1200\/EDBK_433502","article-title":"Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease","volume":"44","author":"Burton","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab (N)-AVD versus brentuximab vedotin (BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Santisteban-Espejo, A., Perez-Requena, J., Atienza-Cuevas, L., Moran-Sanchez, J., Fernandez-Valle, M.D.C., Bernal-Florindo, I., Romero-Garcia, R., and Garcia-Rojo, M. (2021). Prognostic Role of the Expression of Latent-Membrane Protein 1 of Epstein-Barr Virus in Classical Hodgkin Lymphoma. Viruses, 13.","DOI":"10.3390\/v13122523"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Hu, J., Zhang, X., Tao, H., and Jia, Y. (2022). The prognostic value of Epstein-Barr virus infection in Hodgkin lymphoma: A systematic review and meta-analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1034398"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Nohtani, M., Vrzalikova, K., Ibrahim, M., Powell, J.E., Fennell, E., Morgan, S., Grundy, R., McCarthy, K., Dewberry, S., and Bouchal, J. (2022). Impact of Tumour Epstein-Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL. Cancers, 14.","DOI":"10.3390\/cancers14174297"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Satou, A., Takahara, T., and Nakamura, S. (2022). An Update on the Pathology and Molecular Features of Hodgkin Lymphoma. Cancers, 14.","DOI":"10.3390\/cancers14112647"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0344-0338(99)80027-2","article-title":"Basic fibroblast growth factor and fibrosis in Hodgkin\u2019s disease","volume":"195","author":"Ohshima","year":"1999","journal-title":"Pathol.-Res. Pract."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/sj.bjc.6605238","article-title":"Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin\u2019s lymphoma","volume":"101","author":"Birgersdotter","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Ribatti, D., Tamma, R., Annese, T., Ingravallo, G., and Specchia, G. (2022). Inflammatory microenvironment in classical Hodgkin\u2019s lymphoma with special stress on mast cells. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.964573"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/ijc.24389","article-title":"Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin\u2019s lymphoma","volume":"125","author":"Cattaruzza","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ijc.27314","article-title":"Tumor microenvironment composition in pediatric classical Hodgkin lymphoma is modulated by age and Epstein-Barr virus infection","volume":"131","author":"Barros","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_86","first-page":"2187","article-title":"Tumor microenvironment contribution to checkpoint blockade therapy: Lessons learned from Hodgkin lymphoma","volume":"141","author":"Carbone","year":"2023","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: Implications for prognosis and novel therapies","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1189\/jlb.3MR0315-136R","article-title":"The role of T cells in the microenvironment of Hodgkin lymphoma","volume":"99","author":"Wein","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hon.878","article-title":"Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma","volume":"27","author":"Schreck","year":"2009","journal-title":"Hematol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4(+) regulatory T-cell-rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Werner, L., Dreyer, J.H., Hartmann, D., Barros, M.H.M., Buttner-Herold, M., Grittner, U., and Niedobitek, G. (2020). Tumor-associated macrophages in classical Hodgkin lymphoma: Hormetic relationship to outcome. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-66010-z"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.2010.033316","article-title":"Macrophages predict treatment outcome in Hodgkin\u2019s lymphoma","volume":"96","author":"Steidl","year":"2011","journal-title":"Haematologica"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_98","first-page":"2059","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20406207221149245","article-title":"Genetic lesions and targeted therapy in Hodgkin lymphoma","volume":"14","author":"Li","year":"2023","journal-title":"Ther. Adv. Hematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood.2022017147","article-title":"Novel insights into Hodgkin lymphoma biology by single-cell analysis","volume":"141","author":"Aoki","year":"2023","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2929\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:41:29Z","timestamp":1760035289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/17\/2929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,7]]},"references-count":104,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17172929"],"URL":"https:\/\/doi.org\/10.3390\/cancers17172929","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,7]]}}}